TrialBlood2013

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Betty Y Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.